Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
61.8M
-
Number of holders
-
105
-
Total 13F shares, excl. options
-
59.5M
-
Shares change
-
-1.48M
-
Total reported value, excl. options
-
$276M
-
Value change
-
-$11.9M
-
Put/Call ratio
-
0.32
-
Number of buys
-
44
-
Number of sells
-
-64
-
Price
-
$4.64
Significant Holders of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) as of Q1 2025
130 filings reported holding GLUE - Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2025.
Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) has 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 59.5M shares
of 61.8M outstanding shares and own 96.34% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (7.69M shares), PRICE T ROWE ASSOCIATES INC /MD/ (6.64M shares), BVF INC/IL (5.66M shares), Versant Venture Management, LLC (5.65M shares), BAKER BROS. ADVISORS LP (4.92M shares), FMR LLC (4.67M shares), Avoro Capital Advisors LLC (4.65M shares), BlackRock, Inc. (3.77M shares), VANGUARD GROUP INC (3.1M shares), and SUVRETTA CAPITAL MANAGEMENT, LLC (1.56M shares).
This table shows the top 105 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.